Gordon Fried, DO
Interventional Cardiology · East Stroudsburg, PANPI 1134126840
Payments from drug & device makers
Across 1,153 payments — averaging $83.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$78K
- AstraZeneca$2K
- Boehringer Ingelheim$2K
- Amgen$2K
- Boston Scientific$2K
- Novartis$1K
- plus $10K from 32 others
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$63,05066%
- Travel & lodging$10,41211%
- Food & beverage$21,47223%
- Education$1900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 238 | $77,542 |
| AstraZeneca | 83 | $1,976 |
| Boehringer Ingelheim | 91 | $1,870 |
| Amgen | 112 | $1,855 |
| Boston Scientific | 16 | $1,500 |
| Novartis | 105 | $1,390 |
| E.r. Squibb & Sons, L.L.C. | 78 | $1,157 |
| Pfizer | 77 | $1,148 |
| Esperion Therapeutics, Inc. | 52 | $1,060 |
| Merck | 42 | $794 |
| Amarin Pharma, Inc. | 46 | $664 |
| Novo Nordisk | 26 | $602 |
| Amryt Pharma Holdings Ltd | 2 | $600 |
| Bayer | 28 | $531 |
| Abiomed | 12 | $467 |
| Scpharmaceuticals Inc. | 15 | $372 |
| Sanofi-aventis U.S. LLC | 20 | $309 |
| Atricure, Inc. | 4 | $255 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $245 |
| Kowa Pharmaceuticals America, Inc. | 18 | $227 |
| Vifor Pharma, Inc. | 12 | $216 |
| Abbott | 10 | $193 |
| AbbVie | 10 | $129 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $115 |
| Alnylam Pharmaceuticals Inc. | 6 | $115 |
| Actelion Pharmaceuticals US, Inc. | 3 | $107 |
| Lilly USA, LLC | 5 | $97 |
| Regeneron Healthcare Solutions, Inc. | 6 | $93 |
| Kiniksa Pharmaceuticals, Ltd. | 5 | $83 |
| Genentech USA, Inc. | 1 | $74 |
| Baxter Healthcare | 3 | $50 |
| Akcea Therapeutics, Inc. | 2 | $49 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Medtronic | 1 | $22 |
| Sobi, Inc | 1 | $19 |
| Sanofi | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$96,023 in reported general payments places this provider in the 80th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 403 | $486,801 |
| EliquisApixaban | 354 | $389,664 |
| EntrestoSacubitril/Valsartan | 123 | $145,398 |
| JardianceEmpagliflozin | 84 | $97,958 |
| Repatha SureclickEvolocumab | 71 | $65,962 |
| FarxigaDapagliflozin Propanediol | 28 | $28,289 |
| VascepaIcosapent Ethyl | 40 | $27,212 |
| MultaqDronedarone Hcl | 16 | $22,523 |
| BrilintaTicagrelor | 32 | $20,268 |
| Icosapent Ethyl | 24 | $17,067 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $13,350 |
| Ranolazine ErRanolazine | 85 | $12,177 |
| Metoprolol Succinate | 604 | $11,034 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 28 | $10,782 |
| Atorvastatin Calcium | 632 | $7,820 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $77,542 | $486,801403 claims |
| PfizerEliquis | $1,148 | $389,664354 claims |
| NovartisEntresto | $1,390 | $145,398123 claims |
| Boehringer IngelheimJardiance | $1,870 | $97,95884 claims |
| AstraZenecaFarxiga, Brilinta | $1,976 | $48,55760 claims |
| Sanofi-aventis U.S. LLCMultaq | $309 | $22,52316 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $1,060 | $20,84623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 281 interventional cardiology providers in Pennsylvania.
Other interventional cardiology in East Stroudsburg
- William GrayWynnewood$3.3M
- Eric GnallWynnewood$2.4M
- Howard HerrmannPhiladelphia$2.2M
- Ramzi KhalilPittsburgh$1.6M
- Nishant SethiScranton$1.3M
- Matthew BeckerErie$1.3M
- David LasordaPittsburgh$1.1M
- Nainesh PatelAllentown$1.1M
- Jay GiriPhiladelphia$1M
- James HarveyChambersburg$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.